2023
Long-Term Follow-Up of Patients Needing Extracorporeal Membrane Oxygenation Following a Critical Course of COVID-19
GENZOR, Samuel, Pavol POBEHA, Martin SIMEK, Petr JAKUBEC, Jan MIZERA et. al.Základní údaje
Originální název
Long-Term Follow-Up of Patients Needing Extracorporeal Membrane Oxygenation Following a Critical Course of COVID-19
Autoři
GENZOR, Samuel (203 Česká republika, garant), Pavol POBEHA (705 Slovinsko), Martin SIMEK (203 Česká republika), Petr JAKUBEC (203 Česká republika), Jan MIZERA (203 Česká republika), Martin VYKOPAL (203 Česká republika), Milan SOVA (203 Česká republika, domácí), Jakub VANEK (203 Česká republika) a Jan PRASKO (203 Česká republika)
Vydání
LIFE-BASEL, BASEL, MDPI, 2023, 2075-1729
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30203 Respiratory systems
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.200 v roce 2022
Kód RIV
RIV/00216224:14110/23:00131203
Organizační jednotka
Lékařská fakulta
UT WoS
000979236800001
Klíčová slova anglicky
ECMO; COVID-19; long-term outcome
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 11. 7. 2023 10:19, Mgr. Tereza Miškechová
Anotace
V originále
Introduction: Severe respiratory failure is one of the most serious complications of coronavirus disease 2019 (COVID-19). In a small proportion of patients, mechanical ventilation fails to provide adequate oxygenation and extracorporeal membrane oxygenation (ECMO) is needed. The surviving individuals need long-term follow-up as it is not clear what their prognosis is. Aim: To provide a complex clinical picture of patients during follow-up exceeding one year after the ECMO therapy due to severe COVID-19. Methods: All subjects involved in the study required ECMO in the acute stage of COVID-19. The survivors were followed-up for over one year at a specialized respiratory medical center. Results: Of the 41 patients indicated for ECMO, 17 patients (64.7% males) survived. The average age of survivors was 47.8 years, and the average BMI was 34.7 kg center dot m(-2). The duration of ECMO support was 9.4 days. A mild decrease in vital capacity (VC) and transfer factor (DLCO) was observed on the initial follow-up visit (82.1% and 60%, respectively). VC improved by 6.2% and by an additional 7.5% after 6 months and 1 year, respectively. DLCO improved by 21.1% after 6 months and remained stable after 1 year. Post-intensive care consequences included psychological problems and neurological impairment in 29% of patients; 64.7% of the survivors got vaccinated against SARS-CoV-2 within 12 months of hospitalization and 17.6% experienced reinfection with a mild course. Conclusion: The COVID-19 pandemic has significantly increased the need for ECMO. Patients' quality of life after ECMO is temporarily significantly reduced but most patients do not experience permanent disability.